Trials / Active Not Recruiting
Active Not RecruitingNCT04649073
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
A Multicenter, Uncontrolled, Nonrandomized, Open-Label, Phase 1/2 Trial Investigating the Safety and Efficacy of OPC 415 in MMG49 Antigen-Positive Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | OPC-415 | OPC-415 (up to 1×10\^7cells/kg) On 2 days |
Timeline
- Start date
- 2021-02-18
- Primary completion
- 2025-04-09
- Completion
- 2041-01-01
- First posted
- 2020-12-02
- Last updated
- 2025-05-25
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04649073. Inclusion in this directory is not an endorsement.